<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00129376</url>
  </required_header>
  <id_info>
    <org_study_id>GEICAM 2002-03</org_study_id>
    <nct_id>NCT00129376</nct_id>
  </id_info>
  <brief_title>Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients</brief_title>
  <official_title>Multicenter Phase II Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel (T) as Neoadjuvant Treatment for Operable Stage II and IIIA Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Breast Cancer Research Group</source>
  <brief_summary>
    <textblock>
      Treatment consists of 4 AC cycles followed by 2 weekly docetaxel cycles (12 infusions).

      The pathological complete response rate obtained in previous studies is around 12%. The
      expected pathological complete response rate in this study is 25%. With an alpha error of
      0.05 and a beta error of 0.2, and following SimonÂ´s 2 phase test, 19 patients are needed
      initially. With 2 pathological complete responses, patient recruitment will continue until
      approximately 61 patients are recruited. Twelve pathological complete responses are needed to
      confirm the study hypothesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short
      intravenous infusion, every three weeks for four cycles (days 1, 22, 43 and 64). Three weeks
      later, docetaxel (36 mg/m2) was administered as a 30-min intravenous infusion, weekly for six
      weeks (days 85, 92, 99, 106, 113 and 120) followed by a 2-week resting period (8-week cycle).
      After that, patients received a second docetaxel cycle (infusions on days 141, 148, 155, 162,
      169 and 176). Adjuvant chemotherapy and radiotherapy were delivered according to the protocol
      of each participating center. Hormonal treatment was started after the last chemotherapy
      infusion in all patients with positive estrogen and/or progesterone receptor tumors and was
      continued for five years.

      Semiquantitative determination of three molecular markers was carried out by
      immunocytochemical methods. Tissue samples were taken prior to initiation of chemotherapy
      from the core of the primary tumors. Specimens were sent to a central laboratory for analysis
      of Topo II, survivin and p27.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2003</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological Complete Response (pCR) Rate</measure>
    <time_frame>Up to 29 weeks</time_frame>
    <description>Pathological complete response was defined by the Miller &amp; Payne criteria. pCR was defined as no invasive cells identifiable in breast sections at surgery. Response was measured by physical exam and breast imaging before surgery and was evaluated according to the World Health Organization (WHO) criteria. Pathological response after surgery, was based on the proportion of remaining tumor and postchemotherapy changes, evaluating separately the response in the breast and in the axilla lymph nodes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response Rate (CRR)</measure>
    <time_frame>Up to 29 weeks</time_frame>
    <description>CRR measured according to the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions, where:
Complete Response (CR): disappearance of all target lesions
Partial Response (PR): &gt;=30% decrease in the sum of the longest diameter of target lesions
Progresive Disease (PD): &gt;=20% increase from smallest sum of longest diameter recorded since treatment started (best response).
Stable Disease (SD): Neither PD nor PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Over-expression of Topo II (&gt;10% Cells With Nuclear Staining)</measure>
    <time_frame>Up to 29 weeks</time_frame>
    <description>Paraffin-embedded tumors were processed with standard immunocytochemical techniques. Over-expression of Topo II was defined as &gt;10% cells with nuclear staining.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Over-expression of Survivin (&gt;1% Cells With Nuclear Staining)</measure>
    <time_frame>Up to 29 weeks</time_frame>
    <description>Paraffin-embedded tumors were processed with standard immunocytochemical techniques. Tumors with more than 1% of cells with nuclear staining were considered to be over-expressing this protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Over-expression of p27 (&gt;75% Cells With Nuclear Staining)</measure>
    <time_frame>Up to 29 weeks</time_frame>
    <description>Paraffin-embedded tumors were processed with standard immunocytochemical techniques. Sections were rated according to the percentage of tumor cells nuclei with positive staining (1 = &lt; 25%; 2 = between 25-75% and 3 = &gt; 75%).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Doxorubicin+cyclophosphamide - Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short intravenous infusion, every three weeks for four cycles. Later, docetaxel (36 mg/m2) was administered an intravenous infusion, weekly for six weeks followed by a 2-week resting period (8-week cycle).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <arm_group_label>Doxorubicin+cyclophosphamide - Docetaxel</arm_group_label>
    <other_name>adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Doxorubicin+cyclophosphamide - Docetaxel</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Doxorubicin+cyclophosphamide - Docetaxel</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Patients with breast cancer stages II and IIIA, with histological diagnoses as per
             true-cut or open biopsy.

          -  Negative extension study, including bilateral mammography, thoracic x-ray, computed
             tomography (CT)-scan or abdominal echography and bone scintigraphy.

          -  Analysis of hormone receptor status in primary tumour. It is highly recommended to
             obtain a tumour tissue sample before start of treatment, and after definitive surgery.
             These samples will be analysed centrally by Spanish Breast Cancer Research Group
             (GEICAM).

          -  Age &gt;= 18 and &lt;= 70 years old.

          -  Performance status as per Karnofsky index &gt;= 80.

          -  Minimum life expectancy of 6 months.

          -  Electrocardiogram (EKG) 12 weeks before registration to the study. If abnormalities
             are suspected, cardiac function must be assessed by left ventricular ejection fraction
             (LVEF).

          -  Haematology: neutrophils &gt;= 2.0 x10^9/l; platelets &gt;= 100 x10^9/l; hemoglobin &gt;=10
             g/dl.

          -  Hepatic function: total bilirubin &lt;= 1 x upper normal limit (UNL); Aspartate
             aminotransferase (AST) (SGOT) and and Alanine aminotransferase (ALT) (SGPT) &lt;= 2.5 x
             UNL; alkaline phosphatase &lt;= 5 x UNL.

          -  Renal function: creatinine &lt;= 1.5 x UNL; creatinine clearance &gt;= 60 ml/min.

          -  Patients able to comply with study requirements.

          -  Negative pregnancy test.

          -  Adequate contraceptive method during the study and up to 3 months after definitive
             surgery.

        Exclusion Criteria:

          -  Previous systemic therapy for breast cancer treatment.

          -  Previous treatments with anthracyclines or taxanes for any malignancy.

          -  Previous radiotherapy for breast cancer.

          -  Bilateral invasive breast cancer.

          -  Pregnant or lactating women.

          -  Previous motor or sensorial neurotoxicity grade &gt;=2.

          -  Other serious pathologies: congestive heart failure or angina pectoris; history of
             myocardial infarction in the previous year; uncontrolled hypertension (HT) or high
             risk arrhythmias.

          -  History of neurological or psychiatric impairment, precluding patients from providing
             free informed consent.

          -  Active infection.

          -  Active peptic ulcer; unstable diabetes mellitus.

          -  History of previous or current malignancies other than breast cancer, except for basal
             skin carcinoma, cervical in situ carcinoma, other tumour diagnosed and treated more
             than 10 years before, ductal carcinoma in situ (DCIS) or lobular carcinoma in situ
             (LCIS).

          -  Chronic treatment with corticoids unless the treatment started &gt; 6 months before
             registration to the study, and low doses are administered.

          -  Substitutive hormonal therapy. This treatment must be interrupted before inclusion in
             the study.

          -  Concomitant treatment with other investigational products or administration in the 30
             previous days.

          -  Males.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>FundaciÃ³n JimÃ©nez DÃ­az</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario MarquÃ©s de Valdecilla</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CorporaciÃ³ Sanitaria Parc TaulÃ­</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Ribera</name>
      <address>
        <city>Alcira</city>
        <state>Valencia</state>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A CoruÃ±a</name>
      <address>
        <city>A CoruÃ±a</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FundaciÃ³n JimÃ©nez DÃ­az</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.geicam.org</url>
    <description>Click here for more information about this study: GEICAM 2002-03</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 10, 2005</study_first_submitted>
  <study_first_submitted_qc>August 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2005</study_first_posted>
  <results_first_submitted>December 13, 2018</results_first_submitted>
  <results_first_submitted_qc>April 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 5, 2019</results_first_posted>
  <last_update_submitted>April 12, 2019</last_update_submitted>
  <last_update_submitted_qc>April 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stage II and IIIA breast Cancer.</keyword>
  <keyword>Neoadjuvant chemotherapy.</keyword>
  <keyword>Weekly docetaxel.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Doxorubicin + Cyclophosphamide Followed Docetaxel</title>
          <description>Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short intravenous infusion, every three weeks for four cycles (days 1, 22, 43 and 64). Three weeks later, docetaxel (36 mg/m2) was administered as a 30-min intravenous infusion, weekly for six weeks (days 85, 92, 99, 106, 113 and 120) followed by a 2-week resting period (8-week cycle). After that, patients received a second docetaxel cycle (infusions on days 141, 148, 155, 162, 169 and 176).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Doxorubicin + Cyclophosphamide Followed Docetaxel</title>
          <description>Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short intravenous infusion, every three weeks for four cycles (days 1, 22, 43 and 64). Three weeks later, docetaxel (36 mg/m2) was administered as a 30-min intravenous infusion, weekly for six weeks (days 85, 92, 99, 106, 113 and 120) followed by a 2-week resting period (8-week cycle). After that, patients received a second docetaxel cycle (infusions on days 141, 148, 155, 162, 169 and 176).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.43" lower_limit="25" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopausal status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Premenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median Tumor size, cm</title>
          <units>cm</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.8" lower_limit="2.0" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease stage (I, IIA, IIB y IIIA)</title>
          <description>Stage was classified following the TNM system of the American Joint Committee on Cancer (AJCC).
Stage 0. Cancer in situ (âin placeâ). Still located in the place they started and have not spread to nearby tissues. This stage is highly curable, by removing the entire tumor with surgery.
Stage I. Small cancer that has not grown into nearby tissues. Also has not spread.
Stage II and Stage III. Larger cancers that have grown deeply into nearby tissue. They may have also spread to lymph nodes but not to other parts of the body.
Stage IV. Cancer has spread to other organs or parts of the body.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>IIA</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>IIB</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>IIIA</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hormonal receptors (Estrogen Receptor [ER]+/ Progesterone Receptor [PR]+, ER+/PR-, ER-/PR+, ER-/PR-)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>ER+/PR+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ER+/PR-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ER-/PR+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ER-/PR-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathological Complete Response (pCR) Rate</title>
        <description>Pathological complete response was defined by the Miller &amp; Payne criteria. pCR was defined as no invasive cells identifiable in breast sections at surgery. Response was measured by physical exam and breast imaging before surgery and was evaluated according to the World Health Organization (WHO) criteria. Pathological response after surgery, was based on the proportion of remaining tumor and postchemotherapy changes, evaluating separately the response in the breast and in the axilla lymph nodes.</description>
        <time_frame>Up to 29 weeks</time_frame>
        <population>2 patients did not received surgery, 1 because of disease progression, and 1 due to inacceptable toxicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Doxorubicin + Cyclophosphamide Followed Docetaxel</title>
            <description>Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short intravenous infusion, every three weeks for four cycles (days 1, 22, 43 and 64). Three weeks later, docetaxel (36 mg/m2) was administered as a 30-min intravenous infusion, weekly for six weeks (days 85, 92, 99, 106, 113 and 120) followed by a 2-week resting period (8-week cycle). After that, patients received a second docetaxel cycle (infusions on days 141, 148, 155, 162, 169 and 176).</description>
          </group>
        </group_list>
        <measure>
          <title>Pathological Complete Response (pCR) Rate</title>
          <description>Pathological complete response was defined by the Miller &amp; Payne criteria. pCR was defined as no invasive cells identifiable in breast sections at surgery. Response was measured by physical exam and breast imaging before surgery and was evaluated according to the World Health Organization (WHO) criteria. Pathological response after surgery, was based on the proportion of remaining tumor and postchemotherapy changes, evaluating separately the response in the breast and in the axilla lymph nodes.</description>
          <population>2 patients did not received surgery, 1 because of disease progression, and 1 due to inacceptable toxicity.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response Rate (CRR)</title>
        <description>CRR measured according to the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions, where:
Complete Response (CR): disappearance of all target lesions
Partial Response (PR): &gt;=30% decrease in the sum of the longest diameter of target lesions
Progresive Disease (PD): &gt;=20% increase from smallest sum of longest diameter recorded since treatment started (best response).
Stable Disease (SD): Neither PD nor PR</description>
        <time_frame>Up to 29 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Doxorubicin + Cyclophosphamide Followed Docetaxel</title>
            <description>Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short intravenous infusion, every three weeks for four cycles (days 1, 22, 43 and 64). Three weeks later, docetaxel (36 mg/m2) was administered as a 30-min intravenous infusion, weekly for six weeks (days 85, 92, 99, 106, 113 and 120) followed by a 2-week resting period (8-week cycle). After that, patients received a second docetaxel cycle (infusions on days 141, 148, 155, 162, 169 and 176).</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response Rate (CRR)</title>
          <description>CRR measured according to the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions, where:
Complete Response (CR): disappearance of all target lesions
Partial Response (PR): &gt;=30% decrease in the sum of the longest diameter of target lesions
Progresive Disease (PD): &gt;=20% increase from smallest sum of longest diameter recorded since treatment started (best response).
Stable Disease (SD): Neither PD nor PR</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Over-expression of Topo II (&gt;10% Cells With Nuclear Staining)</title>
        <description>Paraffin-embedded tumors were processed with standard immunocytochemical techniques. Over-expression of Topo II was defined as &gt;10% cells with nuclear staining.</description>
        <time_frame>Up to 29 weeks</time_frame>
        <population>20 patient tumor sample could not be evaluated</population>
        <group_list>
          <group group_id="O1">
            <title>Doxorubicin + Cyclophosphamide Followed Docetaxel</title>
            <description>Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short intravenous infusion, every three weeks for four cycles (days 1, 22, 43 and 64). Three weeks later, docetaxel (36 mg/m2) was administered as a 30-min intravenous infusion, weekly for six weeks (days 85, 92, 99, 106, 113 and 120) followed by a 2-week resting period (8-week cycle). After that, patients received a second docetaxel cycle (infusions on days 141, 148, 155, 162, 169 and 176).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Over-expression of Topo II (&gt;10% Cells With Nuclear Staining)</title>
          <description>Paraffin-embedded tumors were processed with standard immunocytochemical techniques. Over-expression of Topo II was defined as &gt;10% cells with nuclear staining.</description>
          <population>20 patient tumor sample could not be evaluated</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&gt; 10%</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&lt; 10%</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Over-expression of Survivin (&gt;1% Cells With Nuclear Staining)</title>
        <description>Paraffin-embedded tumors were processed with standard immunocytochemical techniques. Tumors with more than 1% of cells with nuclear staining were considered to be over-expressing this protein.</description>
        <time_frame>Up to 29 weeks</time_frame>
        <population>17 patient tumor sample could not be evaluated</population>
        <group_list>
          <group group_id="O1">
            <title>Doxorubicin + Cyclophosphamide Followed Docetaxel</title>
            <description>Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short intravenous infusion, every three weeks for four cycles (days 1, 22, 43 and 64). Three weeks later, docetaxel (36 mg/m2) was administered as a 30-min intravenous infusion, weekly for six weeks (days 85, 92, 99, 106, 113 and 120) followed by a 2-week resting period (8-week cycle). After that, patients received a second docetaxel cycle (infusions on days 141, 148, 155, 162, 169 and 176).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Over-expression of Survivin (&gt;1% Cells With Nuclear Staining)</title>
          <description>Paraffin-embedded tumors were processed with standard immunocytochemical techniques. Tumors with more than 1% of cells with nuclear staining were considered to be over-expressing this protein.</description>
          <population>17 patient tumor sample could not be evaluated</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt; 1 %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 1%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Over-expression of p27 (&gt;75% Cells With Nuclear Staining)</title>
        <description>Paraffin-embedded tumors were processed with standard immunocytochemical techniques. Sections were rated according to the percentage of tumor cells nuclei with positive staining (1 = &lt; 25%; 2 = between 25-75% and 3 = &gt; 75%).</description>
        <time_frame>Up to 29 weeks</time_frame>
        <population>20 patient tumor sample could not be evaluated</population>
        <group_list>
          <group group_id="O1">
            <title>Doxorubicin + Cyclophosphamide Followed Docetaxel</title>
            <description>Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short intravenous infusion, every three weeks for four cycles (days 1, 22, 43 and 64). Three weeks later, docetaxel (36 mg/m2) was administered as a 30-min intravenous infusion, weekly for six weeks (days 85, 92, 99, 106, 113 and 120) followed by a 2-week resting period (8-week cycle). After that, patients received a second docetaxel cycle (infusions on days 141, 148, 155, 162, 169 and 176).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Over-expression of p27 (&gt;75% Cells With Nuclear Staining)</title>
          <description>Paraffin-embedded tumors were processed with standard immunocytochemical techniques. Sections were rated according to the percentage of tumor cells nuclei with positive staining (1 = &lt; 25%; 2 = between 25-75% and 3 = &gt; 75%).</description>
          <population>20 patient tumor sample could not be evaluated</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; 75%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 75%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study treatment up to surgery, an average of 26 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Doxorubicin + Cyclophosphamide Followed Docetaxel</title>
          <description>Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short intravenous infusion, every three weeks for four cycles (days 1, 22, 43 and 64). Three weeks later, docetaxel (36 mg/m2) was administered as a 30-min intravenous infusion, weekly for six weeks (days 85, 92, 99, 106, 113 and 120) followed by a 2-week resting period (8-week cycle). After that, patients received a second docetaxel cycle (infusions on days 141, 148, 155, 162, 169 and 176).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI-CTC, version 2.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <description>Left Ventricular Ejection Fraction Grade 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Cardiac-ischemia/infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>NCI-CTC, version 2.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic dysfunction</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scientific Director / Medical Lead / Project Manager</name_or_title>
      <organization>Spanish Breast Cancer Research Group</organization>
      <phone>+34916592870</phone>
      <email>geicam@geicam.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

